SLEEPBIOTICS
DEAD

Serial Number

90801832

Owner

BIOHM HEALTH INC.

Attorney

Brian E. Turung

Filing Date

Jun 29, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SLEEPBIOTICS Trademark

Serial Number: 90801832

SLEEPBIOTICS is a trademark filed by BIOHM HEALTH INC. on June 29, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BIOHM HEALTH INC. (51 trademarks)

425 LITERARY ROAD
CLEVELAND, OH 44113

Entity Type: 99

BIOHM HEALTH LLC (23 trademarks)

CLEVELAND, OH 44113

Entity Type: 16

Trademark Details

Filing Date

June 29, 2021

Registration Date

Not Registered

Published for Opposition

May 31, 2022

Goods & Services

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; dietary supplements for medical use, namely metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal extracts sold as a component ingredient of nutritional supplements and vitamins and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's disease, ulcerative colitis and irritable bowel syndrome

Filing History

ASSIGNED TO EXAMINER
Oct 23, 2025 DOCK
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 30, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 30, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 13, 2024 EXRA
SOU EXTENSION 4 GRANTED
Dec 13, 2024 EX4G
SOU EXTENSION 4 FILED
Nov 27, 2024 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 27, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 2, 2024 EXRA
SOU EXTENSION 3 GRANTED
Oct 2, 2024 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 2, 2024 AITU
NOTICE OF REVIVAL - E-MAILED
Jul 15, 2024 NREV
PETITION GRANTED - EXTENSION REQUEST FILED
Jul 15, 2024 PGEX
ASSIGNED TO PETITION STAFF
Jul 15, 2024 APET
TEAS PETITION TO REVIVE RECEIVED
May 30, 2024 PROA
SOU EXTENSION 3 FILED
May 29, 2024 EXT3
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 29, 2023 EXRA
SOU EXTENSION 2 GRANTED
Nov 28, 2023 EX2G
SOU EXTENSION 2 FILED
Nov 28, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 28, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 1, 2023 EXRA
SOU EXTENSION 1 GRANTED
May 30, 2023 EX1G
SOU EXTENSION 1 FILED
May 30, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
May 30, 2023 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 19, 2023 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 29, 2022 NOAM
NEW NOA TO ISSUE
Oct 17, 2022 NEWN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 28, 2022 NOAM
NOTICE OF ALLOWANCE CANCELLED
Jul 26, 2022 IUCN
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 31, 2022 NPUB
PUBLISHED FOR OPPOSITION
May 31, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 11, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 25, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 21, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 21, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 12, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 10, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 11, 2021 NWOS